Japan’ Nxera Pharma today announces that it has exercised its option to license lucerastat from Idorsia and has entered into ...
German biotech BioNTech and its Chinese partner DualityBio have reported that the Phase III DYNASTY-Breast02 trial of ...
Biopharma research and development has traditionally followed a familiar model. Scientists identified a target, generated ...
The Association of the British Industry (ABPI) has welcomed a Budget measure that removes a value added tax (VAT) charge on ...
Swiss generic and biosimilars drugmaker Sandoz today presented its net-sales performance for the third quarter and first nine ...
Norwegian clinical-stage radiopharma company Oncoinvent, which is developing Radspherin, a receptor-independent ...
US AI native pharmaceutical company Formation Bio today announced the Formation Bio Drug Development Accelerator Fund, with ...
Brinsupri (brensocatib hydrate) reached Japan during the 10 days to October 28, while China recorded the first prescription ...
Swedish biotech AlzeCure Pharma (FN STO: ALZCUR) has appointed co-founder and chief scientific officer Johan Sandin as ...
Pfizer’s Elrexfio meets primary endpoint in second Phase III myeloma trial, with higher infections
US pharma giant Pfizer said its Phase III MagnetisMM-32 trial of Elrexfio (elranatamab), a subcutaneous BCMA-CD3 bispecific antibody, met its primary endpoint at a prespecified interim analysis in ...
The Moscow Arbitration Court has rejected claims of the Russian pharmaceutical manufacturer Grotex to provide a compulsory ...
US biotech Biogen (Nasdaq: BIIB) raised the lower end of its annual earnings guidance after third-quarter revenue rose 11% to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results